Larimar Therapeutics (FRA:ZA71) Common Stock: €0.09 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:ZA71 Larimar Therapeutics Inc FRA:ZA71
41 GF Score
Price €3.26
! 2 Warning Signs
View Full Analysis

What is Larimar Therapeutics Common Stock?

Larimar Therapeutics FRA:ZA71 -9.94% 41 Common Stock is €0.09 Mil as of Mar. 2026. GuruFocus rates FRA:ZA71 with a GF Score™ of 41/100. The stock has 2 warning signs investors should review.

Larimar Therapeutics's quarterly common stock declined from Sep. 2025 (€0.07 Mil) to Dec. 2025 (€0.07 Mil) but then increased from Dec. 2025 (€0.07 Mil) to Mar. 2026 (€0.09 Mil).

Larimar Therapeutics's annual common stock increased from Dec. 2023 (€0.04 Mil) to Dec. 2024 (€0.06 Mil) and increased from Dec. 2024 (€0.06 Mil) to Dec. 2025 (€0.07 Mil).

Larimar Therapeutics Common Stock Historical Data

* Premium members only.

The historical data trend for Larimar Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Larimar Therapeutics Common Stock Chart

Larimar Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial 0.02 0.04 0.04 0.06 0.07

Larimar Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.06 0.07 0.07 0.09
FRA:ZA71
41GF Score
Larimar Therapeutics Inc FRA:ZA71
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Larimar Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of €0.09 Mil mean?
Larimar Therapeutics (FRA:ZA71) has a Common Stock of €0.09 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Larimar Therapeutics and its competitors.
Is Larimar Therapeutics' Common Stock too high?
Larimar Therapeutics' current Common Stock is €0.09 Mil. Overall, Larimar Therapeutics has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Larimar Therapeutics' Common Stock compare to XFOR and CMPX?
Larimar Therapeutics' Common Stock of €0.09 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Larimar Therapeutics and its competitors. Larimar Therapeutics's current Common Stock is €0.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Larimar Therapeutics stock overvalued right now?
Larimar Therapeutics (FRA:ZA71) has a current Common Stock of €0.09 Mil. The current Common Stock is €0.09 Mil. Larimar Therapeutics' overall GF Score™ is 41/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Larimar Therapeutics (FRA:ZA71), the current Common Stock is €0.09 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Larimar Therapeutics Business Description

Other Exchanges LRMR:USA
Address Three Bala Plaza East, Suite 506, Bala Cynwyd, PA, USA, 19004
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
41GF Score

Get the complete analysis for FRA:ZA71

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.26
Price